GLP-1 weight-loss drugs are disrupting U.S. healthcare economics

Wells Fargo released a study indicating that GLP-1 weight-loss drugs are becoming a major economic force in American healthcare, as obesity affects 40.3% of adults and 9.4% are severely obese. Prescription of these drugs surged over 140% from 2022 to 2024, while bariatric surgery volumes fell 34.1% in the same period. Hospital systems must adapt to a model where patients choose a reversible, medication-based solution, potentially reducing surgeries, readmissions, and related complications.

Cardiovascular trials suggest a 20% cut in major events for overweight patients without diabetes, which could further shrink procedural demand. Pharmaceutical development is also shifting, with Deloitte data showing obesity treatments now represent roughly 25% of late-stage pipelines, surpassing oncology for the first time in over a decade. Analysts argue that the sector’s winners will reallocate capital toward obesity medicine, integrated cardiometabolic care, and specialty pharmacy services rather than defending legacy models.